245 related articles for article (PubMed ID: 24125101)
101. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
He W; Eriksson M; Eliasson E; Grassmann F; Bäcklund M; Gabrielson M; Hammarström M; Margolin S; Thorén L; Wengström Y; Borgquist S; Hall P; Czene K
Ann Oncol; 2021 Oct; 32(10):1286-1293. PubMed ID: 34284099
[TBL] [Abstract][Full Text] [Related]
102. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
Lammers LA; Mathijssen RH; van Gelder T; Bijl MJ; de Graan AJ; Seynaeve C; van Fessem MA; Berns EM; Vulto AG; van Schaik RH
Br J Cancer; 2010 Sep; 103(6):765-71. PubMed ID: 20700120
[TBL] [Abstract][Full Text] [Related]
103. Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
Borba MA; Melo-Neto RP; Leitão GM; Castelletti CH; Lima-Filho JL; Martins DB
Pharmacogenomics; 2016 Apr; 17(6):573-82. PubMed ID: 27043475
[TBL] [Abstract][Full Text] [Related]
104. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.
Dezentjé VO; Guchelaar HJ; Nortier JW; van de Velde CJ; Gelderblom H
Clin Cancer Res; 2009 Jan; 15(1):15-21. PubMed ID: 19118028
[TBL] [Abstract][Full Text] [Related]
105. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
[TBL] [Abstract][Full Text] [Related]
106. Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.
Wang H; Ma X; Zhang B; Zhang Y; Han N; Wei L; Sun C; Sun S; Zeng X; Guo H; Li Y; Zhang Y; Zhao J; Qin Z; Liu Z; Zhang N
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e148-e153. PubMed ID: 34196110
[TBL] [Abstract][Full Text] [Related]
107. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
[TBL] [Abstract][Full Text] [Related]
108. CYP2D6 polymorphisms and the impact on tamoxifen therapy.
Beverage JN; Sissung TM; Sion AM; Danesi R; Figg WD
J Pharm Sci; 2007 Sep; 96(9):2224-31. PubMed ID: 17518364
[TBL] [Abstract][Full Text] [Related]
109. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.
Hwang GS; Bhat R; Crutchley RD; Trivedi MV
Pharmacogenomics J; 2018 Apr; 18(2):201-208. PubMed ID: 28762370
[TBL] [Abstract][Full Text] [Related]
110. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.
Dieudonné AS; Lambrechts D; Smeets D; Belmans A; Wildiers H; Paridaens R; Hyonil C; Timmerman D; Christiaens MR; Vergote I; Neven P
Ann Oncol; 2014 Jan; 25(1):90-5. PubMed ID: 24265353
[TBL] [Abstract][Full Text] [Related]
111. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.
Borges S; Desta Z; Jin Y; Faouzi A; Robarge JD; Philips S; Nguyen A; Stearns V; Hayes D; Rae JM; Skaar TC; Flockhart DA; Li L
J Clin Pharmacol; 2010 Apr; 50(4):450-8. PubMed ID: 20081063
[TBL] [Abstract][Full Text] [Related]
112. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
de Vries Schultink AHM; Huitema ADR; Beijnen JH
Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
[TBL] [Abstract][Full Text] [Related]
113. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
Goetz MP; Schaid DJ; Wickerham DL; Safgren S; Mushiroda T; Kubo M; Batzler A; Costantino JP; Vogel VG; Paik S; Carlson EE; Flockhart DA; Wolmark N; Nakamura Y; Weinshilboum RM; Ingle JN; Ames MM
Clin Cancer Res; 2011 Nov; 17(21):6944-51. PubMed ID: 21880792
[TBL] [Abstract][Full Text] [Related]
114. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract][Full Text] [Related]
115. The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.
Zeng Y; Huang K; Huang W
Pak J Pharm Sci; 2017 May; 30(3(Special)):1095-1098. PubMed ID: 28671087
[TBL] [Abstract][Full Text] [Related]
116. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
[TBL] [Abstract][Full Text] [Related]
117. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
[TBL] [Abstract][Full Text] [Related]
118. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
Skaar TC; Desta Z
Clin Pharmacol Ther; 2018 May; 103(5):755-757. PubMed ID: 29473149
[TBL] [Abstract][Full Text] [Related]
119. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
[TBL] [Abstract][Full Text] [Related]
120. Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.
Li J; Czene K; Brauch H; Schroth W; Saladores P; Li Y; Humphreys K; Hall P
Breast Cancer Res; 2013; 15(5):R93. PubMed ID: 24088226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
